Brief: Elicera Enters Agreement With Prominent US Cancer Center
March 6 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* ENTERS AGREEMENT WITH PROMINENT US CANCER CENTER TO
EVALUATE THE
USE OF ITANK IN T-CELL RECEPTOR THERAPIES
Source text for Eikon: ID:nWkr1SBYFG
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent